OATAO - Open Archive Toulouse Archive Ouverte Open Access Week

Polyethylene glycol and prevalence of colorectal adenomas : Population-based study of 1165 patients undergoing colonoscopy

Dorval, Etienne and Jankowski, Jean Marie and Barbieux, Jean-Pierre and Viguier, Jérôme and Bertrand, Philippe and Brondin, Brigitte and Bougnoux, Philippe and Corpet, Denis E. Polyethylene glycol and prevalence of colorectal adenomas : Population-based study of 1165 patients undergoing colonoscopy. (2006) Gastroentérologie clinique et biologique, vol. 3 . pp. 1196-1199. ISSN 0399-8320

[img]
Preview
(Document in English)

PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
200Kb

Official URL: http://tinyurl.com/3froed

Abstract

Background and aim — Dietary polyethylene glycol (PEG) is extraordinarily potent in the chemoprevention of experimental colon carcinogenesis. PEG is used to treat constipation in France and in the USA. French laxatives include Forlax® (PEG4000), Movicol® and Transipeg® (PEG3350), and Idrocol® (pluronic F68). This study tests the hypothesis that use of a PEG-based laxative might reduce the prevalence of colorectal tumors. Methods — In this population-based study, consecutive patients attending for routine total colonoscopy were enrolled during four months by the gastroenterologists of Indre-et-Loire. They were asked if they had previously taken a laxative or a NSAID. Age, gender, previous polyps, family history of colorectal cancer, constipation, digestive symptoms were also recorded. Tumors found during colonoscopy were categorized histologically. Results — Records from 1165 patients fulfilled the inclusion criteria, 607 women and 498 men, mean age 58.3. Among those, 813 had no tumor, 329 had adenomas, and 23 had carcinomas. In a univariate analysis, older age, male gender, lack of digestive symptom, and previous polyps were more common in patients with colorectal tumors. In contrast, previous Forlax® intake was more common in tumor-free patients (odds ratio (OR) any use/no use, 0.52; 95% confidence interval, 0.27-0.94). More people used Forlax®, which contains a higher dose of PEG than the other PEGlaxatives, whose ORs were smaller than one, but did not reach significance. In multivariate analysis, older age and male gender were associated with higher risk, and NSAIDs use with lower risk, of colorectal tumors. Conclusion — Forlax® users had a halved risk of colorectal tumors in univariate analysis, which suggests that PEG may prevent carcinogenesis.

Item Type:Article
Additional Information:Text version (but not publisher's one) is authorized. This article from Gastroentérologie clinique et biologique is online at the Elsevier Masson website : http://www.masson.fr
Audience (journal):International peer-reviewed journal
Uncontrolled Keywords:
Institution:French research institutions > Institut National de la Recherche Agronomique - INRA
Other partners > Hôpital Armand-Trousseau - AP-HP-Trousseau (FRANCE)
Université de Toulouse > Ecole Nationale Vétérinaire de Toulouse - ENVT
Other partners > Association Gastro 37 (FRANCE)
Laboratory name:
Statistics:download
Deposited By:Mathieu Andro

Repository Staff Only: item control page